Compare · BSX vs SENS
BSX vs SENS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $66.37B, about 62.3x SENS ($1.07B).
- Over the past year, BSX is down 57.2% and SENS is down 46.7% - SENS leads by 10.5 points.
- SENS has been more active in the news (4 items in the past 4 weeks vs 2 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Boston Scientific Corporation
- Senseonics Holdings Inc.
- Price
- $44.66-0.23%
- $5.29-1.95%
- Market cap
- $66.37B
- $1.07B
- 1M return
- -7.60%
- -27.63%
- 1Y return
- -57.20%
- -46.73%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 2
- 4
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest SENS
- Director Fiorentino Edward was granted 2,635 shares, increasing direct ownership by 3% to 85,974 units (SEC Form 4)
- Director Prince Douglas S was granted 1,515 shares, increasing direct ownership by 2% to 69,331 units (SEC Form 4)
- Director Roeder Douglas A was granted 2,751 shares, increasing direct ownership by 2% to 157,238 units (SEC Form 4)
- Director Steven Edelman was granted 2,402 shares, increasing direct ownership by 3% to 91,083 units (SEC Form 4)
- Chief Medical Officer Kaufman Francine covered exercise/tax liability with 4,010 shares, decreasing direct ownership by 2% to 177,057 units (SEC Form 4) to cover taxes
- President and CEO Goodnow Timothy T covered exercise/tax liability with 32,598 shares, decreasing direct ownership by 3% to 1,143,748 units (SEC Form 4) (withholding obligation)
- GC & Corp. Development Advisor Horton Kenneth L covered exercise/tax liability with 9,545 shares, decreasing direct ownership by 3% to 285,512 units (SEC Form 4) to satisfy tax liability
- Chief Commercial Officer Hansen Brian B covered exercise/tax liability with 5,420 shares, decreasing direct ownership by 4% to 126,937 units (SEC Form 4) to satisfy tax liability
- Chief Operating Officer Jain Mukul covered exercise/tax liability with 16,194 shares, decreasing direct ownership by 3% to 500,863 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Sullivan Frederick T. covered exercise/tax liability with 5,397 shares, decreasing direct ownership by 2% to 226,477 units (SEC Form 4) to satisfy withholding obligation